Insmed granted additional U.S. patent for ARIKAYCE

Insmed Incorporated announced that the U.S. Patent and Trademark Office has issued patent No. 10,251,900 for certain uses of ARIKAYCE. The claims of the patent relate in part to methods for treating Mycobacterium avium complex lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and the second with an expiry date of May 15, 2035. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration on September 28, 2018, for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. “We are very pleased to receive another patent for ARIKAYCE that reinforces our exclusivity in the U.S. to 2035 for methods that align closely with our approved label, further strengthening our global patent portfolio,” said Will Lewis, Chairman and Chief Executive Officer of Insmed. “In addition, as we advance toward regulatory filings for ARIKAYCE in Europe and Japan, we are continuing to pursue intellectual property protection in these and other major markets worldwide.”
https://thefly.com/landingPageNews.php?id=2890489